<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="433">
  <stage>Registered</stage>
  <submitdate>12/02/2004</submitdate>
  <approvaldate>12/02/2004</approvaldate>
  <nctid>NCT00077792</nctid>
  <trial_identification>
    <studytitle>Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>XRP4563B/3001</secondaryid>
    <secondaryid>EFC6147</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myocardial Infarction</healthcondition>
    <healthcondition>Acute ST-Segment Elevation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Enoxaparin sodium (XRP4563)

Treatment: drugs: Enoxaparin sodium (XRP4563)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of all-cause mortality and non-fatal myocardial re-infarction</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of all-cause mortality, non-fatal myocardial re-infarction, and myocardial ischemia leading to urgent revascularization and non-fatal disabling stroke</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INCLUSION CRITERIA:

        Patients with ST-segment elevation acute myocardial infarction meeting all of the following
        criteria:

          -  Male or non-pregnant female greater than or equal to 18 years of age (depending on
             local regulations, minimal age can vary between 18 and 21 years)

          -  Onset of prolonged (greater than or equal to 20 min) ischemic symptoms at rest less
             than or equal to 6 hours prior to randomization

          -  ST-segment elevation of 0.1 mV in 2 or more limb leads, or 0.2 mV in two (2) or more
             contiguous precordial leads, or left bundle-branch block

          -  Planned reperfusion therapy with streptokinase, tenecteplase, alteplase or reteplase

          -  Written informed consent will be obtained

        EXCLUSION CRITERIA:

        Cardiovascular

          -  Evidence of cardiogenic shock at randomization

          -  Acute pericarditis

          -  History or symptoms suggestive of aortic dissection

          -  MI precipitated by obvious provoking factors such as arrhythmia, infection, severe
             anemia, hyperthyroidism, cocaine, or amphetamine

        Hemorrhagic Risk

          -  Any minor head trauma or any other trauma occurring after the index acute myocardial
             infarction

          -  Active or recent (&lt; 3 months) bleeding including gastrointestinal bleeding, known
             presence of occult blood in the stool, or gross hematuria.

          -  Any history of bleeding diathesis, coagulopathy, platelet disorder, or
             thrombocytopenia

          -  Any single reliable recording of systolic blood pressure &gt;180 mm Hg and/or diastolic
             blood pressure &gt;110 mm Hg prior to randomization

          -  Any history of stroke or transient ischemic attack; any history of hemorrhagic
             cerebrovascular disease

          -  Any known structural damage or other pathologic process involving the central nervous
             system

          -  Any head trauma within 6 months prior to randomization

          -  Major surgery (including CABG), any ophthalmologic surgery, or non-cutaneous biopsy,
             or substantial trauma within 3 months prior to randomization

          -  Traumatic or prolonged cardiopulmonary resuscitation (&gt; 2 minutes) within 2 weeks
             prior to randomization

          -  Puncture of a non-compressible vessel (artery or vein) within the 24 hours prior to
             randomization

          -  Acute peptic ulcer disease within 3 months prior to randomization

        Prior or Concomitant Pharmacologic Therapy

          -  Administration of abciximab (ReoPro), within the previous 7 days or eptifibatide
             (Integrilin), or tirofiban (Aggrastat) within the previous 24 hours prior to
             randomization

          -  Current therapy with oral anticoagulants, or an International Normalized Ratio of &gt;1.5

          -  Administration of a low molecular weight heparin within 8 hours prior to
             randomization.

          -  Known hypersensitivity to low molecular weight heparins, unfractionated heparin or
             heparin-like products; allergy to pork or pork products

          -  Known hypersensitivity and/or contra-indication(s) to fibrinolytic drugs
             (streptokinase, tenecteplase, alteplase and reteplase)

        General

          -  Known platelet count &lt;100,000 cells/microL or history of heparin-induced
             thrombocytopenia

          -  Known clinically significant anemia (Hemoglobin &lt;10 g/dL which is &lt; 6.2 mmol/L)

          -  Known renal insufficiency with serum creatinine &gt;220 mmol/L (2.5 mg/dL) for men and
             &gt;175 mmol/L (2.0 mg/dL) for women when assessed prior to baseline examination.

          -  Advanced neoplastic or other life-threatening disease with a life expectancy of &lt;12
             months

          -  Pregnancy or parturition within the last 90 days or currently breast feeding

          -  Women of childbearing potential except if post-menopausal, surgically sterile or using
             accepted method(s) of birth control or having a negative pregnancy test.

          -  Treatment with other investigational agents in the last 30 days before study entry or
             previous enrollment in ExTRACT-TIMI 25

          -  History of drug or alcohol abuse

          -  Mental condition rendering the patient unable to understand the nature, scope, and
             possible consequences of the study

          -  Any patient unlikely to comply with protocol, e.g., uncooperative attitude, inability
             to return for follow-up visits, and who are unlikely to complete the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20506</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>sanofi-aventis Australia &amp; New Zealand administrative office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Minsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanga√Ø</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Natanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state>Amman</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lysaker</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto Salvo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Bromma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Uruguay</country>
      <state>Montevideo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to determine whether enoxaparin compared to
      unfractionated heparin will reduce the composite endpoint of all-cause mortality and
      non-fatal myocardial re-infarction within 30 days after randomization in patients with acute
      ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00077792</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>